| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Eur J Cardiothorac Surg 2001;20:468-475
© 2001 Elsevier Science NL
a Department of Cardio-thoracic Surgery, Université Catholique de Louvain, Brussels, Belgium
b Department of Nuclear Medicine, Université Catholique de Louvain, Brussels, Belgium
c Department of Radiology, Université Catholique de Louvain, Brussels, Belgium
d Department of Pathology, Université Catholique de Louvain, Brussels, Belgium
Received 9 October 2000; received in revised form 25 May 2001; accepted 27 May 2001.
Corresponding author. Tel.: +32-2-7646107; fax: +32-2-7648960
e-mail: poncelet{at}chir.ucl.ac.be
Objective: To assess the effectiveness of positron emission tomography with radiolabeled [18F]-2-fluoro-deoxy-D-glucose (PET-FDG) imaging in mediastinal lymph node (LN) staging for non-small cell lung carcinoma (NSCLC) and to compare it to conventional clinical and surgical staging. Methods: From June 1998 to February 2000, we enrolled 64 potentially resectable NSCLC patients in a prospective study of PET-FDG imaging of the mediastinum to assess LN involvement. Results of this technique were compared to conventional clinical and surgical staging. Diagnostic efficacy was determined by calculating sensitivity, specificity, overall accuracy, and positive and negative predictive values for each method. Results: PET-FDG imaging correctly identified nodal stage (N0–N1 vs. N2) in 50 out of 61 patients (82%), overstaging occurred in eight patients (13%), and understaging in three patients (4.9%). The sensitivity, specificity, accuracy, and positive and negative predictive values for PET-FDG scan imaging were 67, 85, 82, 43, and 93.6%, respectively. Conventional staging correctly identified nodal stage (N0–N1 vs. N2) in 51 out of 62 patients (82%), overstaging occurred in five patients (8.1%), and understaging in six patients (9.7%). The sensitivity, specificity, accuracy, and positive and negative predictive values for conventional staging were 33, 90.6, 82, 37, and 89%, respectively. With regard to N2 disease, conventional staging showed a poor sensitivity (33%). Indeed, six out of 64 patients were understaged for mediastinal LN involvement. Even though the improvement was not statistically significant (McNemar P=0.08), the combined use of PET-FDG scan and computerized tomography (CT) scan allowed a two-fold increase in the sensitivity of our clinical preoperative staging. Moreover, relying on the PET-scan high negative predictive value might have contributed to a three-fold decrease in the number of required surgical staging procedures. Conclusions: Our study shows that the PET-FDG imaging strength lies in its very high negative predictive value and increased sensitivity. In this study, the overall accuracy of PET-FDG scan (82%) was lower than previously reported. Combined with chest CT-scan preoperatively, it may alleviate the need for surgical staging when PET-FDG studies of the mediastinum are negative. However, with a positive PET-FDG scan result, further diagnostic procedures should be pursued in order to avoid overstaging and allow better surgical patient selection.
Key Words: PET-FDG scan • Non-small cell lung carcinoma • Mediastinal lymph node
This article has been cited by other articles:
|
|
 |
|
  Y. C. Ung, D. E. Maziak, J. A. Vanderveen, C. A. Smith, K. Gulenchyn, C. Lacchetti, W. K. Evans, and Lung Cancer Disease Site Group of Cancer Care Onta 18Fluorodeoxyglucose Positron Emission Tomography in the Diagnosis and Staging of Lung Cancer: A Systematic Review J Natl Cancer Inst, December 5, 2007; 99(23): 1753 - 1767. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. A. Silvestri, M. K. Gould, M. L. Margolis, L. T. Tanoue, D. McCrory, E. Toloza, and F. Detterbeck Noninvasive Staging of Non-small Cell Lung Cancer: ACCP Evidenced-Based Clinical Practice Guidelines (2nd Edition) Chest, September 1, 2007; 132(3_suppl): 178S - 201S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Gregoire, K. Haustermans, X. Geets, S. Roels, and M. Lonneux PET-Based Treatment Planning in Radiotherapy: A New Standard? J. Nucl. Med., January 1, 2007; 48(1_suppl): 68S - 77S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Schimmer, K. Neukam, and O. Elert Staging of non-small cell lung cancer: clinical value of positron emission tomography and mediastinoscopy Interactive CardioVascular and Thoracic Surgery, August 1, 2006; 5(4): 418 - 423. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Birim, A. P. Kappetein, T. Stijnen, and A. J.J.C. Bogers Meta-Analysis of Positron Emission Tomographic and Computed Tomographic Imaging in Detecting Mediastinal Lymph Node Metastases in Nonsmall Cell Lung Cancer Ann. Thorac. Surg., January 1, 2005; 79(1): 375 - 382. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Nomori, K. Watanabe, T. Ohtsuka, T. Naruke, K. Suemasu, and K. Uno The size of metastatic foci and lymph nodes yielding false-negative and false-positive lymph node staging with positron emission tomography in patients with lung cancer J. Thorac. Cardiovasc. Surg., April 1, 2004; 127(4): 1087 - 1092. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. F. Kelly, T. Tran, A. Holmstrom, J. Murar, and R. J. Segurola Jr Accuracy and Cost-Effectiveness of [18F]-2-Fluoro-Deoxy-D-Glucose-Positron Emission Tomography Scan in Potentially Resectable Non-small Cell Lung Cancer Chest, April 1, 2004; 125(4): 1413 - 1423. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. G. Pfister, D. H. Johnson, C. G. Azzoli, W. Sause, T. J. Smith, S. Baker Jr, J. Olak, D. Stover, J. R. Strawn, A. T. Turrisi, et al. American Society of Clinical Oncology Treatment of Unresectable Non-Small-Cell Lung Cancer Guideline: Update 2003 J. Clin. Oncol., January 15, 2004; 22(2): 330 - 353. [Full Text] [PDF]
|
|
|
|
 |
|
 M. K. Gould, W. G. Kuschner, C. E. Rydzak, C. C. Maclean, A. N. Demas, H. Shigemitsu, J. K. Chan, and D. K. Owens Test Performance of Positron Emission Tomography and Computed Tomography for Mediastinal Staging in Patients with Non-Small-Cell Lung Cancer: A Meta-Analysis Ann Intern Med, December 2, 2003; 139(11): 879 - 892. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Toker, Y. Bayrak, S. Tanju, S. Ziyade, O. Eroglu, D. Yilmazbayhan, S. Dilege, and G. Kalayci Invasive staging of superior mediastinum in non-small cell lung cancer patients with specific indications Interactive CardioVascular and Thoracic Surgery, December 1, 2003; 2(4): 472 - 476. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. Cerfolio, B. Ojha, A. S. Bryant, C. S. Bass, A. A. Bartalucci, and J. M. Mountz The role of FDG-PET scan in staging patients with nonsmall cell carcinoma Ann. Thorac. Surg., September 1, 2003; 76(3): 861 - 866. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Venissac, M. Alifano, and J. Mouroux Video-assisted mediastinoscopy: experience from 240 consecutive cases Ann. Thorac. Surg., July 1, 2003; 76(1): 208 - 212. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. Cerfolio, B. Ojha, S. Mukherjee, A. H. Pask, C. S. Bass, and C. R. Katholi Positron emission tomography scanning with 2-fluoro-2-deoxy-D-glucose as a predictor of response of neoadjuvant treatment for non-small cell carcinoma J. Thorac. Cardiovasc. Surg., April 1, 2003; 125(4): 938 - 944. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Kostakoglu, H. Agress Jr, and S. J. Goldsmith Clinical Role of FDG PET in Evaluation of Cancer Patients RadioGraphics, March 1, 2003; 23(2): 315 - 340. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |
